Abstract
Patients infected with human immunodeficiency virus (HIV) are at greater risk of developing non-Hodgkin lymphoma than the general population and aggressive B-cell lymphoma has become one of the most common of the initial acquired immunodeficiency syndrome (AIDS)-defining illnesses. This review considers the prognostic factors and new approaches to the treatment of patients with AIDS-related lymphoma (ARL). As highly active antiretroviral therapy (HAART) became available, the survival of many ARL patients has become comparable to that of HIV-negative patients. This is partly due to the decrease in the incidence of opportunistic infections and improved prognosis. Both developments can also be attributed to new treatment strategies for ARL, such as the use of effective infusional regimens, Rituximab combinations and high-dose therapy with autologous stem-cell transplantation for relapsed disease. However, unresolved issues persist, such as the optimal therapy for patients with Burkitt ARL or central nervous system involvement.
| Original language | English |
|---|---|
| Pages (from-to) | 685-698 |
| Number of pages | 14 |
| Journal | British Journal of Haematology |
| Volume | 136 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Mar 2007 |
Fingerprint
Keywords
- AIDS-related lymphoma
- Highly active antiretroviral therapy
- Peripheral blood stem-cell transplantation
- Prognosis
- Rituximab
ASJC Scopus subject areas
- Hematology
Cite this
Modern management of non-Hodgkin lymphoma in HIV-infected patients. / Mounier, Nicolas; Spina, Michele; Gisselbrecht, Christian.
In: British Journal of Haematology, Vol. 136, No. 5, 03.2007, p. 685-698.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Modern management of non-Hodgkin lymphoma in HIV-infected patients
AU - Mounier, Nicolas
AU - Spina, Michele
AU - Gisselbrecht, Christian
PY - 2007/3
Y1 - 2007/3
N2 - Patients infected with human immunodeficiency virus (HIV) are at greater risk of developing non-Hodgkin lymphoma than the general population and aggressive B-cell lymphoma has become one of the most common of the initial acquired immunodeficiency syndrome (AIDS)-defining illnesses. This review considers the prognostic factors and new approaches to the treatment of patients with AIDS-related lymphoma (ARL). As highly active antiretroviral therapy (HAART) became available, the survival of many ARL patients has become comparable to that of HIV-negative patients. This is partly due to the decrease in the incidence of opportunistic infections and improved prognosis. Both developments can also be attributed to new treatment strategies for ARL, such as the use of effective infusional regimens, Rituximab combinations and high-dose therapy with autologous stem-cell transplantation for relapsed disease. However, unresolved issues persist, such as the optimal therapy for patients with Burkitt ARL or central nervous system involvement.
AB - Patients infected with human immunodeficiency virus (HIV) are at greater risk of developing non-Hodgkin lymphoma than the general population and aggressive B-cell lymphoma has become one of the most common of the initial acquired immunodeficiency syndrome (AIDS)-defining illnesses. This review considers the prognostic factors and new approaches to the treatment of patients with AIDS-related lymphoma (ARL). As highly active antiretroviral therapy (HAART) became available, the survival of many ARL patients has become comparable to that of HIV-negative patients. This is partly due to the decrease in the incidence of opportunistic infections and improved prognosis. Both developments can also be attributed to new treatment strategies for ARL, such as the use of effective infusional regimens, Rituximab combinations and high-dose therapy with autologous stem-cell transplantation for relapsed disease. However, unresolved issues persist, such as the optimal therapy for patients with Burkitt ARL or central nervous system involvement.
KW - AIDS-related lymphoma
KW - Highly active antiretroviral therapy
KW - Peripheral blood stem-cell transplantation
KW - Prognosis
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=33846954413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846954413&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2006.06464.x
DO - 10.1111/j.1365-2141.2006.06464.x
M3 - Article
VL - 136
SP - 685
EP - 698
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 5
ER -